Symphogen and Meiji Seika Kaisha Enter Agreement for Recombinant Polyclonal Antibody Product.COPENHAGEN, Denmark & TOKYO -- Symphogen A/S and Meiji Seika Kaisha Ltd. (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : 2202) announced today that they have entered into a research, development and commercialization agreement that utilizes Symphogen's proprietary antibody discovery technology, Symplexa, to develop a fully human recombinant polyclonal antibody (pAb) product candidate that targets a non-disclosed bacterial pathogen. "We are very pleased to be working with such a well respected company as Meiji," commented Kirsten Drejer, Ph.D., Chief Executive Officer of Symphogen A/S. "This collaboration represents further validation of our drug discovery technology, and may be of significant future value for Symphogen, given our co-development option in the U.S. and E.U. Importantly, this agreement also helps balance our drug development portfolio across proprietary product candidates, fully funded programs, and co-development projects." Under the terms of the agreement, Symphogen will receive an initial technology access fee from Meiji and is eligible to receive development milestone payments as well as royalties on worldwide net sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight from any successfully developed products. Meiji has agreed to fund the development costs associated with the program. Symphogen has retained certain co-development option rights in the United States and European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community . Financial terms were not disclosed. About Symphogen Symphogen is the leader in developing recombinant polyclonal antibodies (pAb), a new class of biopharmaceuticals for the treatment of serious human diseases. By employing its pioneering antibody discovery and manufacturing technologies, Symphogen generates recombinant antibody compositions that capture the diversity and effectiveness of the natural immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Symphogen is building a proprietary product pipeline within several disease areas, including infectious diseases and cancer. Symphogen has established collaborations with international pharmaceutical companies. Symphogen's lead program, Sym001, is planned to enter clinical trials in 2007 and will be the first recombinant polyclonal antibody to enter clinical evaluation clinical evaluation Medtalk An evaluation of whether a Pt has symptoms of a disease, is responding to treatment, or is having adverse reactions to therapy . Sym001 is targeting the treatments of Idiopathic Thrombocytopenic Purpura Idiopathic Thrombocytopenic Purpura Definition Idiopathic thrombocytopenic purpura, or ITP, is a bleeding disorder caused by an abnormally low level of platelets in the patient's blood. (ITP ITP - Intent to Package ) and Hemolytic Disease of Newborns (HDN HDN Hemolytic disease of the newborn, see there ). Symphogen also has development alliances with Biovitrum AB. Symphogen is a private biopharmaceutical company with over 75 employees, based in Copenhagen, Denmark. Refer to www.symphogen.com for further information on Symphogen A/S. About Meiji Seika Kaisha Ltd. Meiji Seika Kaisha, Ltd. is located in Tokyo, Japan and is operating its business in the fields of confectionaries and pharmaceuticals. In the Pharmaceutical division, Meiji is dedicated to the discovery, development and commercialization of a wide variety of pharmaceutical products throughout Japan and some countries outside of Japan, as well. The main areas of its interest are infectious diseases and CNS See Continuous net settlement. CNS See continuous net settlement (CNS). , and Meiji has strong capabilities and expertise in development and commercialization of antibiotic products. For more information on Meiji Seika Kaisha, Ltd. please visit the company's website at www.meiji.co.jp. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion